0001179110-21-001566.txt : 20210210
0001179110-21-001566.hdr.sgml : 20210210
20210210211244
ACCESSION NUMBER: 0001179110-21-001566
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210208
FILED AS OF DATE: 20210210
DATE AS OF CHANGE: 20210210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Epstein David R
CENTRAL INDEX KEY: 0001445826
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38586
FILM NUMBER: 21616297
MAIL ADDRESS:
STREET 1: INTERNATIONAL FLAVORS & FRAGRANCES INC.
STREET 2: 521 W. 57TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Rubius Therapeutics, Inc.
CENTRAL INDEX KEY: 0001709401
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 042688109
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 399 BINNEY STREET, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-679-9600
MAIL ADDRESS:
STREET 1: 399 BINNEY STREET, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2021-02-08
0
0001709401
Rubius Therapeutics, Inc.
RUBY
0001445826
Epstein David R
C/O RUBIUS THERAPEUTICS, INC.
399 BINNEY STREET, SUITE 300
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2021-02-08
4
S
0
89233
14.8837
D
4726220
D
Common Stock
2021-02-09
4
S
0
2100
14.8314
D
4724120
D
Common Stock
2021-02-10
4
S
0
7404
14.7927
D
4716716
D
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $15.05, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $14.90, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $14.87, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Joanne M. Protano, Attorney-in-Fact
2021-02-10